|Table of Contents|

Predictive factors of axillary pathological complete response in neoadjuvant-treated HER-2-positive breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 03
Page:
410-413
Research Field:
Publishing date:

Info

Title:
Predictive factors of axillary pathological complete response in neoadjuvant-treated HER-2-positive breast cancer
Author(s):
LIU Shiwei; ZHANG Purong; ZENG Shiyan; MOU Exian; ZHANG Xin; XU Jia; LI Hui; ZHANG Jianhui
Sichuan Cancer Hospital & Institute，Sichuan Cancer Center，School of Medicine，University of Electronic Science and Technology of China，Sichuan Chengdu 610041，China.
Keywords:
breast cancer; human epidermal growth factor receptor 2; neoadjuvant treatment; axillary pathological complete response; predictive factors
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2021.03.010
Abstract:
Objective：To investigate the predictive factors of axillary pathological complete response(apCR) in human epidermal growth factor receptor 2(HER-2)-positive breast cancer treated with neoadjuvant treatment(NAT).Methods：Data of HER-2-positive breast cancer treated with NAT and radical surgery in the Breast Surgery Center of Sichuan Cancer Hospital from January 2017 to December 2019 was retrospectively reviewed.The Chi-square test or Fisher's exact test was conducted for univariate analyses，and Logistic regression analyses were performed for multivariate analyses.Statistical analyses were conducted using SPSS version 22.0.Results：Ninety-four HER-2-positive patients were included，and the overall apCR rate was 73.4%(69/94).Clinical N0 stage(P=0.005)，negative status of hormone receptor(P=0.008)，anti-HER-2 therapy(P<0.001) and breast pathological complete response(P=0.007) were significantly associated with apCR in univariate analysis.Anti-HER-2 therapy(OR=4.77，95%CI：1.49～15.34，P=0.009) was independently associated with apCR in multivariate analysis.Conclusion： Anti-HER-2 therapy was an independent predictive factor for apCR in neoadjuvant-treated HER-2-positive breast cancer.

References:

[1]BURSTEIN HJ，CURIGLIANO G，LOIBL S，et al.Estimating the benefits of therapy for early-stage breast cancer：The St.Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019［J］.Ann Oncol，2019，30（10）：1541-1557.
[2]SLAMON DJ，CLARK GM，WONG SG，et al.Human breast cancer：correlation of relapse and survival with amplification of the HER-2/neu oncogene［J］.Science，1987，235（4785）：177-182.
[3]杨伟斌，刘志毅，曹宽，等.表皮生长因子受体家族特点及与肿瘤关系的研究进展［J］.现代肿瘤医学，2019，27(2)：346-351. YANG WB，LIU ZY，CAO K，et al.Research progress on the characteristics of epidermal growth factor receptor family and its relationship with tumors［J］.Modern Oncology，2019，27(2)：346-351.
[4]CORTAZAR P，ZHANG L，UNTCH M，et al.Pathological complete response and long-term clinical benefit in breast cancer：The CTNeoBC pooled analysis［J］.Lancet，2014，384（9938）：164-172.
[5]VON MINCKWITZ G，UNTCH M，BLOHMER JU，et al.Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes［J］.J Clin Oncol，2012，30（15）：1796-1804.
[6]VON MINCKWITZ G，HUANG CS，MANO MS，et al.Trastuzumab emtansine for residual invasive HER-2-positive breast cancer［J］.N Engl J Med，2019，380（7）：617-628.
[7]HAMMOND ME，HAYES DF，DOWSETT M，et al.American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer［J］.J Clin Oncol，2010，28（16）：2784-2795.
[8]WOLFF AC，HAMMOND MEH，ALLISON KH，et al.Human epidermal growth factor receptor 2 testing in breast cancer：American society of clinical oncology/college of American pathologists clinical practice guideline focused update［J］.J Clin Oncol，2018，36（20）：2105-2122.
[9]ELSTON CW，ELLIS IO.Pathological prognostic factors in breast cancer.The value of histological grade in breast cancer：Experience from a large study with long-term follow-up［J］.Histopathology，2002，41（3A）：154-161.
[10]HENNESSY BT，HORTOBAGYI GN，ROUZIER R，et al.Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy［J］.J Clin Oncol，2005，23（36）：9304-9311.
[11]MOUGALIAN SS，HERNANDEZ M，LEI X，et al.Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy［J］.JAMA Oncol，2016，2（4）：508-516.
[12]MURPHY BL，L HOSKIN T，HEINS CDN，et al.Preoperative prediction of node-negative disease after neoadjuvant chemotherapy in patients presenting with node-negative or node-positive breast cancer［J］.Ann Surg Oncol，2017，24（9）：2518-2525.
[13]SAMIEI S，VAN NIJNATTEN TJA，DE MUNCK L，et al.Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy［J］.Ann Surg，2020，271（3）：574-580.
[14]LOIBL S，GIANNI L.HER-2-positive breast cancer［J］.Lancet，2017，389（10087）：2415-2429.
[15]张国泰，符德元.三阳性乳腺癌的治疗进展［J］.现代肿瘤医学，2020，28(4)：687-690. ZHANG GT，FU DY.The advance of treatment in triple-positive breast cancer［J］.Modern Oncology，2020，28(4)：687-690.
[16]GIANNI L，EIERMANN W，SEMIGLAZOV V，et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone，in patients with HER-2-positive locally advanced breast cancer（the NOAH trial）：A randomised controlled superiority trial with a parallel HER-2-negative cohort［J］.Lancet，2010，375（9712）：377-384.
[17]GIANNI L，PIENKOWSKI T，IM YH，et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced，inflammatory，or early HER-2-positive breast cancer（NeoSphere）：A randomised multicentre，open-label，phase 2 trial［J］.Lancet Oncol，2012，13（1）：25-32.

Memo

Memo:
-
Last Update: 2020-12-31